The insulin delivery devices market size was valued at USD 17.73 billion in 2024 and is expected to reach USD 32.57 billion by 2032, growing at a CAGR of 7.92% over the forecast period of 2025-2032.
The insulin delivery devices market size is growing due to a high incidence rate of diabetes mellitus around the world, technological advancements, and increasing patient awareness in diabetes management. The prevalence of diabetes has been estimated to have affected 537 million adults in 2021 and is expected to reach 643 million by 2030 (IDF). This increasing burden is driving the need for more convenient delivery systems, such as insulin pens, pumps, and AID systems. Moreover, advancements including tubeless insulin pumps and closed-loop systems, and increasing acceptance of wearable technology are some factors creating demand for the insulin delivery devices market.
A March 2025 NEJM Evidence report emphasized favorable results of advanced automated insulin delivery systems, with enhanced glycemic control in adolescents, contributing to provider receptivity.
Market acceleration is compounded by regulatory support provided by newly updated Endocrine Society guidelines and growing FDA approvals for digital insulin delivery technologies. Escalating R&D funding in the form of smart insulin and AI-incorporated delivery platforms, along with favorable reimbursement policies for the best part of the U.S. and Europe, is also shaping the market landscape. More than 30% of people with type 1 diabetes in the U.S. are currently on a pump, so there is a definite move toward these devices for insulin therapy. Increasing healthcare expenditure and public-private partnerships to improve supply chains and access to devices, led to opportunities in the insulin delivery devices market size and forecast.
For instance, Medtronic and Insulet Corporation, two players in the insulin delivery devices market, introduced AI-based insulin pump technologies that enable personalized insulin delivery, a testament to the continued expansion and innovation in the global insulin delivery devices market.
Market Dynamics:
Drivers:
Innovations, Rising Prevalence, and Regulatory Advancements Fueling the Market Growth
The insulin delivery devices market is pushed by increasing diabetes population, technological advancements, and changes in clinical guidelines. Between 2021 and 2045, the global diabetes population will grow by almost 51%, leading to a sustained need for effective insulin delivery modalities.
Rising use of smart insulin pens and patch pumps, such as the wearable "CeQur Simplicity", is boosting patient adherence. In a 2024 article in Clinical Diabetes, insulin pen use grew by 35% between 2018 and 2023 due to ease and accuracy gains. Moreover, the increasing geriatric population, which is generally prone to type 2 diabetes, is widening the user base. Both the FDA and EMA have recently approved a variety of next-generation insulin delivery solutions, facilitating the route to market access for new technologies.
R&D investments are also on the rise, with companies such as Novo Nordisk and Tandem Diabetes Care committing more than 12% of their revenue to device innovation, fueling the growth of the market. Collaborations between med-tech companies and AI vendors have driven progress in closed-loop systems. The global insulin delivery devices market share will continue to expand as new Thing reimbursement models to the form in the U.S. and Europe, and supply chain improvements AND increased manufacturing investments make these technologies more widely available.
Restraints:
High Costs, Technological Barriers, and User Education Limit Adoption, also Hinder Market Expansion
The high out-of-pocket cost of more advanced devices, such as insulin pumps and continuous glucose monitoring (CGM) systems, acts as a deterrent, especially among middle-income and uninsured individuals. A study in the JMCP in 2024 found that more than 40% of diabetes patients in the U.S. reported that cost was a barrier to their use of more modern insulin delivery systems. Complex device interfaces and care needs can also become barriers, particularly for older patients or those with lower levels of health literacy. In addition, variations in technology between locations may lead to unequal equipment distribution and supply chain disruptions.
Regulatory and reimbursement challenges still exist; for instance, while the U.S. has had some success in securing CMS coverage for insulin pumps, many other markets have little to no coverage policies, which in turn limit device penetration. Furthermore, inadequate physician training and patient education lead to poor use and compliance. Another study, which is PubMed-indexed, reveals that more than 25% of the patients terminate insulin pump therapy within the first year for reasons of problems with device manipulation and side effects. These issues, along with slow innovation approvals in certain territories, restrict the market share of insulin delivery devices and make the effectiveness of life-changing technologies less powerful. Continued focus on affordability, availability, and awareness is important to sustain the insulin delivery devices market growth.
By Product
In 2024, insulin pens held the largest share of the insulin delivery systems market by product, with a share of 48.6%. They are popular as they are simple, portable, requiring less training in use, with less tendency to dosing errors, and thus preferred by the patients and more so by those who control Type 2 diabetes. Pre-load features and ease of use increase patient adherence and convenience. Additionally, the rise in several connected smart insulin pens has expanded acceptance in developed and developing markets.
Insulin pumps are expected to be the fastest-growing product type during the forecast period. The insulin delivery systems market growth is driven by increasing awareness about the benefits of intensive insulin therapy, technological advancements in automated insulin delivery devices, and increasing reimbursement for CGM devices in Type 2 diabetes patients. The rise of tubeless systems and wearable pumps, such as patch pumps, and the increasing integration with CGM, have played a key role in this trend, especially among younger and technology crowds.
By End Use
The homecare application dominated the insulin delivery devices market in 2024 and accounted for 52.2% of the value. The growing preference for diabetes self-management and increased penetration of user-friendly insulin delivery devices and remote patient monitoring tools are mainly responsible for the larger share of this segment. There is yet another driver of home-based care: it cuts costs and hospital visits, which is turning out to be more and more palatable to insurers and patients.
The hospitals and clinics department segment is projected to witness the fastest growth. Such growth is due to the growing volume of diabetes related hospital admissions, improvements to in-hospital insulin delivery processes, and the rising prominence of hospital-based diabetes education programs. Better healthcare infrastructure and early detection campaigns, and advanced insulin devices in institutional care are also assisting in the fast growth of this segment.
Regional Analysis:
Based on region, North America contributed the highest share, holding 45.2% in 2024, and is estimated to dominate in terms of revenue share during the forecast period, owing to the higher prevalence of diabetes, robust healthcare infrastructure, and reimbursement. The U.S. insulin delivery devices market size was valued at USD 6.06 billion in 2024 and is expected to reach USD 9.91 billion by 2032, growing at a CAGR of 6.40% over the forecast period of 2025-2032, due to the early adoption of advanced technology, an increasing awareness level of diabetes, and a large population using insulin pumps. More than 37 million people in the U.S. have diabetes, driving ongoing demand for new insulin delivery options, the CDC reports. Strong regional market presence is augmented by the presence of key players, including Medtronic and Insulet.
The Canada insulin delivery devices market is also growing on account of elevating Type 1 diabetes occurrence along with the increased availability of advanced insulin delivery devices under the government health programs. Mexico is growing with more government initiatives to address diabetes and increased access to healthcare, though affordability and education are obstacles in rural areas.
Europe is a developed insulin delivery devices market with organized diabetes care programs, well-defined national diabetes management guidelines, and national and regional policies reducing out-of-pocket expenditure. Germany is the leader in the region owing to a robust public health system, a large population of diabetics, and early penetration of insulin pump treatment. The U.K./France market is enjoying strong penetration of wearable insulin technologies, thanks to their progressive health policies. Mentioning also that Germany has more than 8,500,000 diabetics in 2023 (a very big demand pool). Poland and Turkey are experiencing rapid growth in the use of insulin pens driven by government reimbursement and more patient education. The second-fastest growing area after Asia Pacific, Europe is prioritizing digital health and telemonitoring, driving the use of devices outside healthcare facilities.
Asia Pacific insulin delivery devices market is the fastest growing region owing to the presence of the largest diabetic population globally, especially in India and China, and increasing healthcare expenditures and awareness. China prevails due to its enormous diabetic population (more than 140 million in 2023), rapid urbanization, and policy-led diabetes screening initiatives. The Indian market is growing by leaps and bounds due to the increasing young diabetic population, also owing to the easy availability of insulin pens, and local production of the devices at lower costs. Autonomous systems have been adopted in Japan and South Korea as well, stimulated by the environment with a well-developed health technology ecosystem.
The LAMEA region is growing at a steady pace, limited by deficiencies in infrastructure and affordability. Brazil is the largest market in Latin America, driven by government diabetes programs and a burgeoning private health system, and Argentina is experiencing higher insulin pump uptake thanks to expanding insurance coverage. In the Middle East, Saudi Arabia is top of the table on account of its high diabetes burden (nearly 18% of the population), and state-led health reforms under Vision 2030.
Leading insulin delivery devices companies operating in the market comprise Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Ypsomed AG, Medtronic, Insulet Corporation, B. Braun SE, Owen Mumford Ltd., Tandem Diabetes Care, Inc., and BD (Becton, Dickinson, and Company).
In May 2025, CeQur Simplicity obtained FDA clearance for 4-day wearable mealtime insulin delivery, simplifying diabetes management with extended wearability.
In April 2025, Embecta received FDA clearance for a next-generation insulin delivery system, supporting innovation in user-centric therapy options.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 17.73 Billion |
| Market Size by 2032 | USD 32.57 Billion |
| CAGR | CAGR of 7.92% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Insulin Pens (Reusable Insulin Pens, Disposable Insulin Pens), Insulin Pumps (Patch Pumps, Tethered Pumps), Insulin Pen Needles (Standard Pen Needles, Safety Pen Needles), Insulin Syringes, and Other Products) • By End Use (Hospitals & Clinics, Homecare, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Ypsomed AG, Medtronic, Insulet Corporation, B. Braun SE, Owen Mumford Ltd., Tandem Diabetes Care, Inc., and BD (Becton, Dickinson and Company). |
Ans: The Insulin Delivery Devices Market is projected to grow at a CAGR of 7.92% during the forecast period.
Ans: By 2032, the Insulin Delivery Devices Market is expected to reach USD 32.57 billion, up from USD 17.73 billion in 2024.
Ans: The insulin delivery devices market is pushed by increasing diabetes population, technological advancements, and changes in clinical guidelines.
Ans: The high out-of-pocket cost of more advanced devices such as insulin pumps and continuous glucose monitoring (CGM) systems acts as a deterrent, especially among middle-income and uninsured individuals.
Ans: North America is the dominant region in the Insulin Delivery Devices Market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Diabetes Incidence and Prevalence, 2024
5.2 Insulin Prescription Trends, by Region (2024)
5.3 Healthcare Spending on Diabetes Management, by Region (2024)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Insulin Delivery Devices Market Segmentation By Product
7.1 Chapter Overview
7.2 Insulin Pens
7.2.1 Insulin Pens Market Trend Analysis (2021-2032)
7.2.2 Insulin Pens Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Reusable Insulin Pens
7.2.3.1 Reusable Insulin Pens Market Trend Analysis (2021-2032)
7.2.3.2 Reusable Insulin Pens Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Disposable Insulin Pens
7.2.4.1 Disposable Insulin Pens Market Trend Analysis (2021-2032)
7.2.4.2 Disposable Insulin Pens Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Insulin Pumps
7.3.1 Insulin Pumps Market Trends Analysis (2021-2032)
7.3.2 Insulin Pumps Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Patch Pumps
7.3.3.1 Patch Pumps Market Trends Analysis (2021-2032)
7.3.3.2 Patch Pumps Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Tethered Pumps
7.3.4.1 Tethered Pumps Market Trends Analysis (2021-2032)
7.3.4.2 Tethered Pumps Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Insulin Pen Needles
7.4.1 Insulin Pen Needles Market Trends Analysis (2021-2032)
7.4.2 Insulin Pen Needles Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.3 Standard Pen Needles
7.4.3.1 Standard Pen Needles Market Trends Analysis (2021-2032)
7.4.3.2 Standard Pen Needles Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.4 Safety Pen Needles
7.4.4.1 Safety Pen Needles Market Trends Analysis (2021-2032)
7.4.4.2 Safety Pen Needles Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Insulin Syringes
7.5.1 Insulin Syringes Market Trends Analysis (2021-2032)
7.5.2 Insulin Syringes Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Other Products
7.6.1 Other Products Market Trends Analysis (2021-2032)
7.6.2 Other Products Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Insulin Delivery Devices Market Segmentation By End Use
8.1 Chapter Overview
8.2 Hospitals & Clinics
8.2.1 Hospitals & Clinics Market Trends Analysis (2021-2032)
8.2.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Homecare
8.3.1 Homecare Market Trends Analysis (2021-2032)
8.3.2 Homecare Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2021-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Insulin Delivery Devices Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.2.4 North America Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.2.5.2 USA Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.2.6.2 Canada Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.2.7.2 Mexico Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Insulin Delivery Devices Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.4 Europe Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.5.2 Germany Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.6.2 France Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.7.2 UK Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.8.2 Italy Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.9.2 Spain Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.10.2 Poland Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.11.2 Turkey Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Insulin Delivery Devices Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.4 Asia Pacific Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.5.2 China Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.5.2 India Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.5.2 Japan Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.6.2 South Korea Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.7.2 Singapore Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
8.4.8.2 Australia Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Insulin Delivery Devices Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.5.2 UAE Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.7.2 Qatar Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.8.2 South Africa Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Insulin Delivery Devices Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.6.4 Latin America Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.6.5.2 Brazil Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.6.6.2 Argentina Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Insulin Delivery Devices Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Insulin Delivery Devices Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10. Company Profiles
10.1 Novo Nordisk A/S
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 Sanofi
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Eli Lilly and Company
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Ypsomed AG
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Medtronic
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Insulet Corporation
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 B. Braun SE
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Owen Mumford Ltd.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 Tandem Diabetes Care, Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 BD (Becton, Dickinson and Company)
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
Insulin Pens
Reusable Insulin Pens
Disposable Insulin Pens
Insulin Pumps
Patch Pumps
Tethered Pumps
Insulin Pen Needles
Standard Pen Needles
Safety Pen Needles
Insulin Syringes
Other Products
By End Use
Hospitals & Clinics
Homecare
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
